CHF 5633

Drug Profile

CHF 5633

Alternative Names: CHF5633

Latest Information Update: 19 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chiesi; Karolinska Institute; Swedish University of Agricultural Sciences
  • Developer Chiesi
  • Class Pulmonary surfactants
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Neonatal respiratory distress syndrome

Most Recent Events

  • 24 May 2018 Chiesi Farmaceutici completes a phase II trial in Neonatal respiratory distress syndrome in USA (Intratracheal) (NCT02452476)
  • 01 Jan 2016 Phase-II clinical trials in Neonatal respiratory distress syndrome in USA (Intratracheal) (NCT02452476)
  • 26 May 2015 Chiesi plans a phase II trial for Neonatal respiratory distress syndrome in USA (NCT02452476)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top